Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome

Linda Cucciniello(University of Udine), Fabio Puglisi(University of Udine), Filippo Montemurro(Roche (Switzerland)), Giuliana Pavone(University of Catania), Claudia Martinelli(University of Naples Federico II), Mario Giuliano(Regione Campania), Giovanna Garufi(Agostino Gemelli University Polyclinic), Rossana Di Rienzo(University of Naples Federico II), Lucia Del Mastro(Ospedale Policlinico San Martino), Grazia Arpino(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cancer Treatment Reviews
September 7, 2023
10.1016/j.ctrv.2023.102624
Cited by 58

Related Papers

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545